MLS PHARMA (0781.947.583): financials and annual accounts

MLS PHARMA

Neupré ·KBO/BCE: BE 0781.947.583

Line	2025	2024	2023	2022
Balance sheet: assets
`20/58`	662,546	522,577	334,454	177,672
`20`	-	-	0	0
`21/28`	13,413	5,853	-	-
`22/27`	13,413	5,853	-	-
`23`	6,982	4,957	-	-
`24`	6,431	896	-	-
`29/58`	649,134	516,724	334,454	177,672
`40/41`	2,047	3,629	2,736	2,267
`40`	2,047	-	0	1,058
`41`	-	3,629	2,736	1,209
`50/53`	97,015	-	-	-
`54/58`	544,618	509,600	326,539	174,928
`490/1`	5,454	3,495	5,178	477
Balance sheet: equity and liabilities
`10/49`	662,546	522,577	334,454	177,672
`10/15`	437,939	415,384	250,994	133,533
`10/11`	5,000	-	-	-
`13`	-	169,390	5,000	5,000
`130/1`	-	0	-	-
`133`	-	169,390	5,000	5,000
`14`	432,939	245,994	245,994	128,533
`17/49`	224,607	107,193	83,459	44,138
`42/48`	224,607	107,193	83,459	44,138
`44`	-	58	7,336	1,683
`440/4`	-	58	7,336	1,683
`45`	104,446	107,135	76,123	42,455
`450/3`	104,446	107,135	72,623	38,955
`454/9`	-	-	3,500	3,500
`47/48`	120,161	-	-	0
Income statement
`9900`	256,948	241,734	151,791	169,255
`630`	2,064	260	-	1,331
`640/8`	3,153	3,657	571	404
`9901`	251,731	237,818	151,221	167,520
`75/76B`	1,797	192	72	60
`75`	1,797	192	72	60
`65/66B`	1,219	153	164	92
`65`	159	153	164	92
`66B`	1,060	-	-	-
`9903`	252,310	237,857	151,129	167,489
`67/77`	54,754	73,468	33,668	38,955
`9904`	197,555	164,390	117,461	128,533
`9905`	197,555	164,390	117,461	128,533
Appropriation of the result
`9906`	443,550	410,384	245,994	128,533
`14P`	245,994	245,994	128,533	-
`791/2`	164,390	-	-	-
`691/2`	-	164,390	-	-
`6921`	-	164,390	-	-
`794`	0	-	-	-
`694/7`	175,000	-	-	-
`694`	175,000	-	-	-
Document	PDF	PDF	PDF	PDF

Financial year	Type	Filed	Reference	Document
31-12-2025	micro format	06-07-2026	2026-00264388	PDF
31-12-2024	micro format	08-08-2025	2025-00370661	PDF
31-12-2023	micro format	26-08-2024	2024-00384890	PDF
31-12-2022	micro format	30-08-2023	2023-00400847	PDF

2025	2024	2023	2022
253,795	238,078	-	168,851
199,619	164,649	-	129,864
9,623	6,113	-	1,331
35,018	183,061	151,611	-
424,527	409,531	250,994	133,533
66.1%	79.5%	75.0%	75.2%
2.89	4.82	4.01	4.03
0.51	0.26	0.33	0.33
45.1%	39.6%	46.8%	96.3%
29.8%	31.5%	35.1%	72.3%
over 100	over 100	-	over 100

MLS PHARMA